syn 1

α-syn aggregation inhibitor-1 (Compound 2e) acts as an inhibitor of α-syn aggregation. It is capable of inhibiting the cell viability of SH-SY5Y.

SYN1143 (AMG-1) is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and 4 nmol L, respectively.

Tau-0N4R-IN-1 (Compound 6T) is a brain-penetrant inhibitor of tau0N4R oligomerization. It effectively inhibits the fibrillization of tau 0N4R, 2N3R, and 2N4R, showcasing potent anti-seeding effects against tau in vitro, and can dose-dependently reduce α-syn oligomerization while preventing the formation of α-syn inclusions. Tau-0N4R-IN-1 demonstrates stability in mouse microsomes and reduces Aβ plaques derived from the brain tissue of AD patients. Moreover, it exhibits favorable pharmacokinetic properties in mice.

α-Synuclein inhibitor 3 (Compound 7g) is a potent inhibitor of α-synuclein (α-Syn) aggregation, with potential applications in Parkinson's disease research [1].

α-Synuclein inhibitor 6 (compound 3ge) is a blood-brain barrier-permeable agent that effectively inhibits α-Synuclein (α-Syn) aggregation, demonstrating a potent IC50 value of 1.70 μM and achieving an inhibition ratio of 94.4% at 30 μM [1].

Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity, tau aggregation, and α-syn oligomers, with an IC50 value of 119 nM for Dyrk1A kinase.

Sycosterol A is an α-synuclein (α-syn) inhibitory sterol.

Maysin, a neuroprotective C-glycosyl-flavone isolated from corn silk, protects against Syn amyloid aggregates-oligomers and fibrils-induced damage by preventing oxidative stress and intracellular calcium imbalance through autophagic activation. It is utilized in Parkinson's disease (PD) research [1].

D-685, a prodrug of D-520, demonstrates enhanced anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model compared to its parent compound D-520. It effectively reduces the buildup of human α-synuclein (α-syn) protein and readily penetrates the brain [1].

SQ-3, a quinoline analogue, demonstrates moderate selectivity towards α-synuclein aggregates (α-syn aggregates) (K i = 39.3 nM) over β-amyloid (Aβ) aggregates (K i = 230 nM). [18 F]SQ-3 exhibits foundational characteristics as a potential lead compound in developing an effective α-synuclein imaging probe [1].

α-Synuclein inhibitor 9 (Compound 20C) targets and binds to cavities within mature α-synuclein fibrils, diminishing their β-sheet content. It effectively inhibits the aggregation of A53T α-synuclein, exhibits neuroprotective properties, enhances brain functionality, and alleviates motor impairments. This compound is utilized in research related to Parkinson's disease (PD). [1]

Tau protein α-synuclein-IN-1 is a dual inhibitor that not only impedes tau protein and α-synuclein but also reduces the development of α-syn inclusions in M17D neuroblastoma cells, making it a useful agent in the study of Alzheimer's disease [1].

Ellagic acid 4-O-α-L-arabinopyranoside, extracted from Dimocarpus longan Lour. (syn. Euphoria longan Lam.), exhibits antioxidative activity [1].